DealsMay 4, 2026, 07:02 AM
BioCryst Licenses Navenibart in Europe for $70M Upfront
AI Summary
BioCryst Pharmaceuticals announced an exclusive license agreement with an Irish affiliate of Neopharmed Gentili to commercialize navenibart for hereditary angioedema (HAE) in Europe. BioCryst will receive $70 million upfront, with eligibility for up to $275 million in future regulatory and sales milestone payments, plus tiered royalties on net sales from 18% to 30%. This deal strengthens BioCryst's financial position and leverages an existing partnership, while the Phase 3 program for navenibart in HAE remains on track for a US regulatory filing by the end of 2027.
Key Highlights
- BioCryst granted Neopharmed Gentili exclusive rights to commercialize navenibart for HAE in Europe.
- BioCryst will receive a $70 million upfront payment.
- The company is eligible for up to $275 million in future regulatory and sales milestone payments.
- BioCryst will also receive tiered royalties on net sales ranging from 18% to 30%.
- The navenibart Phase 3 program for HAE is on track for US regulatory filing by end of 2027.
- This agreement builds on a prior deal for the sale of European ORLADEYO® business to Neopharmed Gentili in 2025.